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literature about special meanings of the phase angle as REFERENCES
compared to Xc are flawed by inconsistent comparisons 1. Piccoli A, Pillon L, Tabbi` MG: Major confounders for reactance
as a marker of malnutrition in hemodialysis patients. Kidney Intamong groups with different vector lengths.
56:2311–2312, 1999Body impedance (from either whole-body or body seg-
2. Piccoli A, for the Italian HD-BIA Study Group: Identification
ments, measured in either single or multiple frequency) of operational clues to dry weight prescription in hemodialysis using
bioimpedance vector analysis. Kidney Int 53:1036–1043, 1998is described by a complex number, or vector Z. The
3. Piccoli A, Nigrelli S, Caberlotto A, Bottazzo S, Rossi B, Pillonbivariate vector Z can be represented in the real-imagi-
L, Maggiore Q: Bivariate normal values of the bioelectrical imped-
nary plane (that is, rectangular coordinates) as a combi- ance vector in adult and elderly populations. Am J Clin Nutr 61:269–
270, 1995nation of R (the opposition to flow of an alternating
4. Piccoli A, Pittoni G, Facco E, Pillon L: Relationship betweencurrent through intra- and extracellular ionic solutions, central venous pressure and bioimpedance vector analysis in criti-
representing the real part of Z) and Xc (the capacitance cally ill patients. Crit Care Med 28:132–137, 2000
produced by tissue interfaces and cell membranes, repre-
senting the imaginary part of Z at every current fre-
quency) across soft tissues (fat plus fat-free mass without Statistical error inbone). The impedance vector Z can alternatively be repre-
sented in the polar coordinates with two other compo- pamidronate study?
nents, magnitude [jZj 5 =(R2 1 Xc2)] and direction (that
To the Editor: The paper by Fan et al, recently pub-is, phase angle 5 arctan Xc/R). In statistical analysis, the
lished in Kidney International [1], addresses a very impor-bell-shaped distribution of both vector components and
tant question, as discussed in an Editorial in the sametheir mutual correlation allow easy handling of Z as
issue [2].a bivariate, normal, random vector in the rectangular
The authors conclude: “This study has shown that thecoordinate system (such as a probability RXc graph [2–3]).
early rapid bone loss that occurs in men during the first 12In the literature and in practice, in subjects with a
months after renal transplantation can be prevented by twocomparable R value (comparable vector length), greater
intravenous doses of pamidronate given at transplantationXc values (greater phase angles) are observed in subjects
and one month later. The regimen was simple to administer,with greater soft tissue mass (such as obese people and
well tolerated and potentially applicable to other clinicalathletes) as compared to subjects with lower Xc values
groups of glucocorticoid treatment patients.”(smaller phase angles) and reduced soft tissue mass (lean-
It might be so, but it is doubtful whether the authorsness, malnutrition, cachexia). However, great phase angles
have shown this to be the case. The authors randomized 26of long vectors (high Xc and R values) are observed in
male patients undergoing renal transplantation to receivedehydration (for example, cholera, post-dialysis), even
either placebo (500 mL 0.9% saline, N 5 12) or intrave-with malnutrition and poor prognosis, and reduced phase
nous pamidronate (0.5 mg/kg wt in 500 mL 0.9% saline,angles of short vectors (reduced Xc and R values) are
N 5 14) at the time of transplantation and again oneobserved in fluid overload (edema, pre-dialysis) even
month later. The primary effect parameters were changeswith good nutrition and prognosis [1, 2, 4]. Indeed, the
in bone mineral density (BMD) at the lumbar spine andsmaller inter-subject variability of the phase angle as
at the femoral neck after 12 months. There was a 6 to 9%compared to Xc readings, due to the correlation between
decrease in BMD after 12 months compared to baselineR and Xc, does not reduce the inverse, strong effect of
in the placebo group, whereas there was no significanttissue hydration on phase angle. Thus, only considering
decrease after 12 months in the pamidronate group. How-the phase angle and neglecting vector length necessarily
ever, when performing a clinical randomized placebo-con-finds a better (worse) nutrition and prognosis at the end
trolled study, the changes in the effect parameters in the(start) of a dialysis session (Fig. 4 in [2]).
intervention group have to be compared to the changes inIn conclusion, trivial errors can be avoided by plotting
the placebo group with an appropriate statistical methodvectors at appropriate, bivariate reference intervals (tol-
before any conclusion on the effect of the interventionerance ellipses) [3], and looking carefully at either the
can be made. This was not reported in the paper by FanR reading or vector length before stating the patient’s
et al [1]. The authors did not present numbers that allowprognosis in terms of Xc or phase angle, respectively.
the readers to do the proper analysis on their own, but
from the figures given, it seems unlikely that there wereAntonio Piccoli, Luana Pillon, and Maria-Grazia Tabbi`
University of Padova, Italy, and University of California, statistically significant differences in the changes in BMD
San Francisco, California, USA at the lumbar spine or at the femoral neck between the
pamidronate group and the placebo group. This might be
due to a type II error, that is, a lack of statistical power
due to the relatively small number of subjects in the study.Ó 2000 by the International Society of Nephrology
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It would be appropriate if the authors report on the reveals that the mean T score at the femoral neck was
comparisons between the changes in BMD between the significantly lower than at the lumbar spine (20.89 6 0.32
pamidronate and the placebo group, and if statistically vs. 20.20 6 0.37, P , 0.05). The finding that cortical
insignificant, to report the type II error given the observed osteopenia is greater than cancellous osteopenia in dialysis
differences and the number of subjects, and then to make patients has also been documented by other investigators
a more appropriate conclusion. [2]. Accelerated cortical bone loss driven by secondary
hyperparathyroidism [3, 4] may explain the distribution
Ole Lander Svendsen of bone loss at different sites in dialysis patients. OurCopenhagen, Denmark
previously published work also documented that after
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ments of Nephrology and Endocrinology P2131, Rigshospitalet, Univer-
greater at the femoral neck than at the lumbar spine [5].sity of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.
E-mail: ols@rh.dk These findings suggest that protection of the skeleton from
the consequences of hyperparathyroidism may explain the
REFERENCES apparent greater benefit of pamidronate at this predomi-
nantly cortical site.1. Fan SL-S, Almond MK, Ball E, Evans K, Cunningham J: Pamidro-
nate therapy as prevention of bone loss following renal transplanta- We believe, therefore, that the data conclusively point
tion. Kidney Int 7:684–690, 2000 to beneficial effects of pamidronate at the femoral neck,2. Weber TJ, Quarles LD: Prevention bone loss after renal transplanta-
and probably at the lumbar spine as well, albeit with lesstion with biphosphonates: We can—but should we? (Editorial) Kidney
Int 57:735–737, 2000 certainty.
Reply from the authors J. Cunningham and S.L.S. Fan
London, England, United KingdomDr. Svendsen makes the valid points that intergroup
analysis of the outcomes after therapy or placebo should
be performed and that as the numbers of patients in this REFERENCES
study is small, the risk of a type II error cannot be dis- 1. Fan SL-S, Almond MK, Ball E, Evans K, Cunningham J: Pamidro-
counted, at least with respect to the lumbar spine data. nate therapy as prevention of bone loss following renal transplanta-
tion. Kidney Int 57:684–690, 2000Using both nonparametric (Mann-Whitney U) test and
2. Schober HC, Han ZH, Foldes AJ, Shih MS, Rao DS, Balena R,unpaired Student’s t-test, we have compared the changes
Parfitt AM: Mineralized bone loss at different sites in dialysis patients:
in bone mineral density (BMD) in the control group with Implications for prevention. J Am Soc Nephrol 9:1225–1233, 1998
those in the pamidronate-treated group 12 months after 3. Kleerekoper M, Villanueva AR, Mathews CHE, Rao DS, Pumo
B, Parfitt AM: PTH-mediated bone loss in primary and secondaryrenal transplantation. At the femoral neck, patients who
hyperparathyroidism, in Clinical Disorders of Bone and Mineralwere treated with pamidronate lost less bone compared
Metabolism, edited by Frame B, Potts JT, Amsterdam, Excerpta
with control (P , 0.002 for both tests). However, at the Medica, 1983, p 200
lumbar spine, there were no intergroup differences, al- 4. Parfitt AM: Accelerated cortical bone loss: Primary and secondary
hyperparathyroidism, in Current Concepts in Bone Fragility, editedthough as stated in the paper [1], within group comparison
by Uhthoff H, New York, Springer-Verlag, 1986, p 279showed significant loss in control but no such loss in the
5. Almond MK, Kwan JT, Evans K, Cunningham J: Loss of regional
pamidronate treatment group. bone mineral density in the first 12 months following renal trans-
plantation. Nephron 66:52–57, 1994The baseline study of regional BMD in our patients
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